Business Context and Reporting Period
This Form 8-K was filed by Pavmed Inc. on March 28, 2022. The report details a material definitive agreement entered into by Lucid Diagnostics Inc., a majority-owned subsidiary of Pavmed, with CF Principal Investments LLC (an affiliate of Cantor Fitzgerald).
Key Financial Metrics and Transaction Details
- Facility Type: Committed equity facility (Common Stock Purchase Agreement).
- Maximum Capacity: Up to $50.0 million in Lucid Diagnostics common stock.
- Upfront Cost: Lucid paid Cantor $1,000,000 as consideration for the irrevocable commitment.
- Pricing Mechanism: Shares will be sold at 96% of the volume-weighted average price on the trading date of the sale notice.
- Ownership Cap: Sales are limited to 7,482,763 shares (19.99% of outstanding voting power) unless shareholder approval is obtained.
- Investor Ownership Limit: Cantor cannot beneficially own more than 4.99% of Lucid's outstanding voting power.
- Term: The facility is available for 36 months following the effective date of the resale registration statement.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Unusual Items
The filing does not report changes to historical revenue, profit, or cash flow. The material change is the establishment of a new financing mechanism. Notable terms include:
- Discretionary Sales: Lucid determines the timing and amount of sales based on market conditions.
- Termination Rights: Lucid may terminate the agreement at any time after commencement with three trading days' prior written notice, at no cost or penalty.
- Parent Company Impact: No shares of Pavmed Inc.'s common stock will be offered or sold under this agreement; the transaction is specific to the Lucid subsidiary.
Guidance, Outlook, and Risks
Management Commentary: The facility is structured similarly to a traditional at-the-market equity facility, allowing for periodic capital raising. Proceeds are intended for working capital and general corporate purposes.
Risks and Contingencies:
- Registration Requirement: The facility cannot commence until a resale registration statement is declared effective by the SEC.
- Dilution Risk: Issuance of up to 19.99% of Lucid's outstanding shares could dilute existing shareholders.
- Market Dependency: The ability to raise capital depends on market conditions and the trading price of Lucid's common stock.
Investor Verification Checklist
- Verify the effective date of the Resale Registration Statement to confirm when the facility becomes active.
- Monitor the $1,000,000 upfront payment impact on Lucid's immediate cash position.
- Track future sales notices to assess the actual amount raised versus the $50.0 million capacity.
- Review the 19.99% ownership cap to understand the maximum potential dilution without further shareholder approval.
- Confirm that no Pavmed Inc. parent-level shares are being issued under this specific agreement.